Abiopharma

🔍 ALBA MANUEL (Director)

Company: Astera Labs, Inc. (ALAB)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 57,001 shares of Common Stock at $106.3194 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,517,497.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 24,317 shares of Common Stock at $107.4443 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,493,180.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 45,668 shares of Common Stock at $108.3324 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,447,512.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 15,367 shares of Common Stock at $109.1027 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,432,145.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Sold 5,060 shares of Common Stock at $110.2112 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,427,085.00 | transaction_form_type: 4 | Footnotes: F1, F7, F3
• Sold 2,587 shares of Common Stock at $111.1412 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,424,498.00 | transaction_form_type: 4 | Footnotes: F1, F8, F3
• Sold 33,000 shares of Common Stock at $107.6141 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 319,863.00 | transaction_form_type: 4 | Footnotes: F1, F9, F10
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: By spouse | shares_owned_after: 5,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: H | shares_owned_after: 2,351.00

Footnotes:

• F1: The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2025.
• F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.8500 to $106.8400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: These shares are owned directly by Manuel Alba-Marquez in trust for Alba 2003 Living Trust (the "Alba Trust"), of which the Reporting Person and his spouse are co-trustees. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $106.8500 to $107.8400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.8500 to $108.8400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $108.8500 to $109.8400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $109.8500 to $110.8300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.8500 to $111.2700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.6124 to $107.6148, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F10: These shares are owned directly by Casa Alameda 2007, LLC, of which the Reporting Person is a manager. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.